Ocugen, Inc. (2H51.F)

1,5570 +0,0120 (+0,78%) Ab 10:07AM CEST. Markt geöffnet.

Ocugen, Inc.

11 Great Valley Parkway
Malvern, PA 19355
United States
484 328 4701
https://www.ocugen.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 65

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Shankar Musunuri M.B.A., Ph.D.	Co-Founder, CEO & Chairman	804,23k	N/A	1964
Dr. Uday B. Kompella Ph.D.	Co-founder & Independent Director	55,83k	N/A	1967
Dr. Arun Upadhyay Ph.D.	Chief Scientific Officer and Head of Research & Development	556,52k	N/A	1983
John Kouch J.D.	General Counsel	N/A	N/A	N/A
Ms. Tiffany J. Hamilton M.B.A.	AVP & Head of Corporate Communications	N/A	N/A	N/A
Ms. Kristen Craft	Head of People & Culture	N/A	N/A	N/A
Mr. Michael Shine M.B.A.	Senior Vice President of Commercial	N/A	N/A	N/A
Ms. Jyothy Pillai M.S.	VP & Head of Regulatory & Quality	N/A	N/A	N/A
Dr. Huma Qamar CMI, M.D., M.P.H.	Chief Medical Officer	N/A	N/A	1984
Dr. Durgaprasad Annavajjula Ph.D.	VP, Head of Program Management & Chief of Staff	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Corporate Governance

Ocugen, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 10. Die grundlegenden Scores sind Audit: 9, Vorstand: 7, Shareholderrechte: 8, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.